Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry

Fabiola Atzeni, Piercarlo Sarzi-Puttini, Costantino Botsios, Antonio Carletto, Paola Cipriani, Ennio Giulio Favalli, Elena Frati, Valentina Foschi, Stefania Gasparini, AnnaRita Giardina, Elisa Gremese, Florenzo Iannone, Marco Sebastiani, Tamara Ziglioli, Domenico Biasi, Clodoveo Ferri, Mauro Galeazzi, Roberto Gerli, Roberto Giacomelli, Roberto GorlaMarcello Govoni, Giovanni Lapadula, Antonio Marchesoni, Fausto Salaffi, Leonardo Punzi, Giovanni Triolo, Gianfranco Ferraccioli

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF therapy on the basis of the data included in the GISEA register. Methods: The study involved 2769 adult patients with long-standing RA (mean age 53.2 ± 13.4. years; mean disease duration 9.0 ± 8.3. years) enrolled in the GISEA register, who had been treated for at least 6. months with TNF inhibitors or had discontinued therapy due to SI: 837 (30%) treated with infliximab (IFN), 802 (29%) with adalimumab (ADA), and 1130 (41%) with etanercept (ETN). Results: 176 patients had experienced at least one of the 226 Sis during the 9. years of treatment with an anti-TNF agent, an overall incidence of 31.8/1000 patient-years (95% CI 25.2-38.3): 23.7/1000 patient-years (95% CI 13.1-34.2) on ADA; 12.8/1000 patient-years (95% CI 6.3-19.4) on ETN and 65.1/1000 patient-years (95% CI 48.4-81.8) on IFN. The risk was higher in the first than in the second year of treatment, but this difference was not statistically significant (p = 0.08) (38.9% of the SIs were recorded in the first 12. months of treatment). The risk of SI was significantly different among the three treatment groups (p <0.0001). Multivariate models confirmed that the use of steroids (p <0.046), concomitant DMARD treatment during anti-TNF therapy (p = 0.004), advanced age at the start of anti-TNF treatment (p <0.0001), and the use of IFN or ADA rather than ETN (respectively p <0.0001 and p = 0.023) were strong and statistically significant predictors of infection. Conclusions: Anti-TNF therapy is associated with a small but significant risk of SI that is associated with the concomitant use of steroids, advanced age at the start of anti-TNF treatment, and the type of anti-TNF agent.

Original languageEnglish
Pages (from-to)225-229
Number of pages5
JournalAutoimmunity Reviews
Volume12
Issue number2
DOIs
Publication statusPublished - Dec 2012

Keywords

  • Anti-TNF agents
  • GISEA register
  • Infections
  • Predictive factors

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry'. Together they form a unique fingerprint.

Cite this